EURETINA 2020 Virtual - Programme Schedule

Programme ScheduleProgramme Overview
EURETINA Sessions Keynotes Symposia Instructional Courses Free Paper Abstracts Poster Abstracts Prize Papers All Days Fri 2nd Sat 3rd Sun 4th Load Favourites

Please note that all times are in Central European Summer Time (CEST)

Programme Filter
timer Loading ... please wait
Fri 02 11:00 - 11:45 CEST
Chairperson(s):
U. Schmidt-Erfurth AUSTRIA,  A. Loewenstein ISRAEL

Channel 1

11.00
U. Schmidt-Erfurth AUSTRIA
Neovascular AMD: AI evidence on novel grounds

11.06
S. Sivaprasad UK
Diabetic retinopathy severity: Diagnostic and therapeutic guidance

11.12
R. Tadayoni FRANCE
Surgery of (pseudo) holes: Standards in macular surgery

11.18
A. Loewenstein ISRAEL
Heads-up surgery: More options than ever

11.24
TBC
The myopia pandemic: The European response

11.30
Discussion

11.45
End of session

Fri 02 12:00 - 12:45 CEST
Chairperson(s):
A. Laidlaw UK,  J. Garcia-Arumi SPAIN

Channel 1

12.00
B. Corcóstegui SPAIN
Encirclement: what does it do? when to use it?

12.05
J. Garcia-Arumi SPAIN
PVR, when how and what to peel

12.10
T. Williamson UK
Retinectomy in PVR: early vs late

12.15
J.C. Pastor SPAIN
Risks with Tamponade agents

12.20
TBC
Realistic expectations in complex RRD

12.25
Discussion

12.45
End of session

Fri 02 14:00 - 14:45 CEST
Chairperson(s):
R. Schlingemann THE NETHERLANDS,  E. Midena ITALY

Channel 1

14.00
E. Pilotto ITALY
Retinopathy in Type 1 diabetic children

14.06
A. Fawzi USA
Retinal blood flow in diabetic retinopathy

14.12
M. Paques FRANCE
Deferred laser in DME: follow ETDRS or aim for TelCaps?

14.18
N. Bressler USA
Current and future DRCRnet protocols in diabetic retinopathy

14.24
A. Laidlaw UK
Surgical solutions for DR, when to go in

14.30
Discussion

14.45
End of session

Fri 02 15:00 - 15:45 CEST
Chairperson(s):
S. Wolf SWITZERLAND,  N. Eter GERMANY

Channel 1

15.00
P. Keane UK
Artificial Intelligence in OCT and fundus images: Overview

15.07
T. Peto UK
Artificial Intelligence for DR screening

15.11
R. Tadayoni FRANCE
From DRSS to new imaging and AI

15.15
R. Sznitman SWITZERLAND
Biomarker detection in OCT scans

15.19
S. Sadda USA
Deep learning for assessment of AMD biomarkers

15.23
R. Schwartz UK
Using deep learning to detect reticular pseudodrusen on the UK Biobank – results and implications

15.27
Discussion

15.45
End of session

Fri 02 16:00 - 16:45 CEST
Chairperson(s):
K. Rezaei USA,  R. Tadayoni FRANCE

Channel 1

16.00
M. Berrocal PUERTO RICO
Rescue the View

16.01
Discussion

16.04
J. Garcia Arumi SPAIN
Lens Dislocation and Retinal Detachment in Marian Syndrome

16.05
Discussion

16.08
C. Claes BELGIUM
Oops, no way to make sclerotomies

16.09
Discussion

16.12
K. Kadonosono JAPAN
Limiting Phototoxicity During 3D Vitrectomy for Retinitis Pigmentosa

16.13
Discussion

16.16
X. Li CHINA
Air-Fluid Exchange…

16.17
Discussion

16.20
A. Maia BRAZIL
Retinal Detachment with Suprachoroidal Hemorrhage

16.21
Discussion

16.24
G. Pertile ITALY
Subretinal Injection of Membrane Blu Dual

16.25
Discussion

16.28
S. Priglinger GERMANY
Submacular Perfluoron

16.29
Discussion

16.32
S. Rizzo ITALY
Disposable Cryo

16.33
Discussion

16.36
D. Steel UK
Perfluoron Guided Subretinal TPA

16.37
Discussion

16.40
R. Tadayoni FRANCE
TBD

16.41
Discussion

16.45
End of session

Sat 03 08:30 - 09:15 CEST
Chairperson(s):
F. G. Holz GERMANY, G. Staurenghi ITALY, A. Tufail UK

Channel 1

08.30
TBC
New insights from epidemiological studies

08.35
A. Tufail UK
Managing AMD patients: impact of AI-based biomarker detection in OCT scans

08.40
R. Guymer AUSTRALIA
Approaches to slow progression of intermediate AMD

08.45
Discussion

08.52
J. Mones SPAIN
Novel therapeutic approaches for neovascular AMD – better efficacy/longer duration?

08.57
C. Regillo USA
Long-acting drug delivery in nAMD: ARCHWAY phase 3 results

09.02
A. Loewenstein ISRAEL
Improving adherence and outcomes in AMD therapy: Home monitoring

09.07
Discussion

09.15
End of session

Sat 03 09:30 - 10:15 CEST
Chairperson(s):
A. Loewenstein ISRAEL,  N. Eter GERMANY

Channel 1

09.30
R. Schlingemann THE NETHERLANDS
New insights in the pathophysiology of diabetic macular edema in vein occlusion

09.36
P. Lanzetta ITALY
The management of macular edema in vein occlusion

09.42
J. Garcia-Arumi SPAIN
The surgical management of resistant cases of vein occlusion

09.48
F. Bandello ITALY
Is OCT-A essential in vein occlusion?

09.54
U. Schmidt-Erfurth AUSTRIA
Artificial intelligence in vascular retinal disease

10.00
Discussion

10.15
End of session

Sat 03 10:30 - 11:15 CEST
Chairperson(s):
J. Garcia-Arumi SPAIN,  J. van Meurs THE NETHERLANDS

Channel 1

10.30
B. Bodaghi FRANCE
Viral retinitis

10.36
A. Adan SPAIN
New strategies with biologics in uveitis 

10.42
F. Pichi UNITED ARAB EMIRATES
OCTA in uveitis

10.48
J. van Meurs THE NETHERLANDS
Earlier antibiotic treatment is the most feasible step to improve treatment of endophthalmitis

10.54
J. Garcia-Arumi SPAIN
Surgical treatment of endophthalmitis

11.00
Discussion

11.15
End of session

Sat 03 13:45 - 14:30 CEST
Chairperson(s):
C.C.W. Klaver THE NETHERLANDS,  R. Finger GERMANY

Channel 1

13.45
R. Finger GERMANY
AMD risk and progression.

13.52
A. Schuster GERMANY
Glaucoma onset and progression

13.59
T. Peto UK
Diabetic eye diseases (DR & DME) onset, development of treatable stages, visual prognosis

14.06
C. Delcourt FRANCE
Diet and eye disease

14.13
Discussion

14.30
End of session

Sat 03 15:45 - 16:30 CEST
Chairperson(s):
A. Loewenstein ISRAEL,  A. Tufail UK, S. Wolf SWITZERLAND, F. G. Holz GERMANY

Channel 1

15.45
Impact of COVID on Retina Care: the aftermath

Panel
A. Tufail UK
A. Lowenstein Israel
F. G. Holz GERMANY
S. Wolf SWITZERLAND
J. Garcia-Arumi SPAIN
C. Mariotti ITALY
L. Kodjikian FRANCE
J. Francois Korobelnik FRANCE

15.54
How does safe spacing/PPE affect the delivery of care – can we continue to be cost-effective?

Panel
R. Hamilton UK
S. Wolf SWITZERLAND
J. Garcia-Arumi SPAIN
J. Francois Korobelnik FRANCE

16.03
Should we alter our surgical environment?

Panel
R. Tadayoni FRANCE
A. Laidlaw UK
F. G. Holz GERMANY
J. Garcia-Arumi SPAIN
C. Mariotti ITALY

16.12
Is virtual the new reality? The Good, the Bad and the Ugly – Efficiency of virtual consults, conferences, and teaching

Panel
F. G. Holz GERMANY
A. Lowenstein Israel
A. Tufail UK
R. Tadayoni FRANCE
E. Midena ITALY

16.21
What have we learned from the COVID-disruption that we should keep?

Panel
F. G. Holz GERMANY
A. Lowenstein Israel
A. Tufail UK
S. Wolf SWITZERLAND

16.30
End of session

Sat 03 16:45 - 17:30 CEST
Chairperson(s):
R. Tadayoni FRANCE, J. Garcia-Arumi SPAIN, K. Rezaei USA

Channel 1

16.45
M. Michaelides UK
Phase 1/2 Clinical Trial of AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 9-month Results

16.50
F. G. Holz GERMANY
Zimura A Novel C5 Inhibitor, Significantly Reduces the Mean Rate of Geographic Atrophy Growth in the GATHER1 Clinical Trial

16.55
R. Tadayoni FRANCE
Oculis OCS-01 Phase 2 Study Results: A Topical Therapeutic for DME

17.00
R. Avery USA
RGX-314 Gene Therapy: Ongoing Phase I/IIa Interim Results

17.05
S. Sadda USA
Impact of pegcetocoplan on progression of nascent geographic atrophy in AMD

17.10
R. Tadayoni FRANCE
Investigating adverse events of intraocular inflammation with retinal vasculitis and/or retinal vascular occlusion in patients treated with brolucizumab

17.15
S. Khan UK
A Global Review of Publicly Available Datasets for Ophthalmic Imaging: Recognising Barriers to Access, Usability and Generalisability

17.20
G. Staurenghi ITALY, S. Charles USA, P. Keane UK
Innovation Discussions: 2020 News and Innovation in imaging, surgery, artificial intelligence

17.30
End of session

Sun 04 09:30 - 10:15 CEST
Chairperson(s):
C.C.W. Klaver THE NETHERLANDS,  M. Zinkernagel SWITZERLAND, R. Schlingemann THE NETHERLANDS

Channel 1

09.30
C. C.W. Klaver THE NETHERLANDS
New insights in retinal disease derived from the EyeRisk study

09.37
TBC
Lessons learnt from single cell transcriptomics of the retina

09.44
TBC
Vascular-Glia-Neuron interactions in the retina

09.51
C. Sanchez THE NETHERLANDS
From screen to bedside: how to implement AI in the management of retinal disease?

09.58
Discussion

10.15
End of session

Sun 04 10:30 - 11:15 CEST
Chairperson(s):
R. Tadayoni FRANCE, Xiaoxin Li CHINA

Channel 1

10.30
K. Ohno-Matsui JAPAN
Ultra wide-field imaging of pathologic myopia

10.36
X. Li CHINA
Transmissions of OCT in PIC, PIC-CNV and M-CNV

10.42
L. Lu CHINA
Three years outcome of macular buckling for macularhole and foveoschisis in high myopic eyes

10.48
Y. Ikuno JAPAN
Surgical approach for myopic macular diseases

10.54
T. Ho TAIWAN
Thinking processes and practices in the management of vitreoretinal interface disorders in pathologic myopia

11.00
Discussion

11.15
End of session

Sun 04 10:45 - 11:30 CEST
Chairperson(s):
R. Schlingemann THE NETHERLANDS,  G. Querques ITALY

Channel 2

10.45
D. Sarraf USA
PAMM VS AMN: Brothers in Arms or Strangers in the Night

10.51
S. Sadda USA
PEVAC

10.57
R. Schlingemann THE NETHERLANDS
Retinal vascular abnormalities associated with leakage and hard exudates, Telcaps and others

11.03
B. Leroy BELGIUM
Decision making in rare hereditary retinal disease

11.09
T. Wolfensberger SWITZERLAND
Surgical challenge-subject TBD

11.15
Discussion

11.30
End of session

Sun 04 12:30 - 13:15 CEST
Chairperson(s):
J.F. Kiilgaard DENMARK,  H. Heimann UK

Channel 1

12.30
C. Maschi FRANCE
Diagnosis and treatment of peripheral exudative haemorrhagic chorioretinopathy

12.35
H. Annas THE NETHERLANDS
Retinal Hemeangiomas – new insights in genetics

12.39
R. Hussain UK
PDT for choroidal haemangioma – long-term outcomes and treatment of recurrent exudative retinopathy

12.43
Discussion

12.50
E. Midena ITALY
Challenges in radiation induced macula oedema

12.54
H. Heimann UK
Photodynamic therapy of choroidal melanoma

12.58
E. Kilic THE NETHERLANDS
Molecular genetics and clinical implications in uveal melanoma

13.02
TBC
Treatment of Metastatic Uveal Melanoma

13.07
Discussion

13.15
End of session

EURETINA 2020 Virtual

Frank Holz

Prof. Frank G. Holz, FEBO, FARVO

University Eye Hospital Bonn
EURETINA President

Dear Colleagues,

We are delighted to announce EURETINA 2020 Virtual, taking place from 2-4 October, and delivering the highest quality scientific content curated by world-renowned experts in the field of retina.

The Virtual Congress will present up to 4 Channels of scientific content, to include EURETINA Sessions & Keynotes on Channel 1, International Symposia on Channel 2, Instructional Courses on Channel 3, as well as a fourth Channel running on Saturday to present the highest scoring Free Papers.

Having extensively researched the most favourable and engaging formats for this new digital landscape, session times have been reduced to 45 minutes, to present engaging, shortened presentations with live discussion throughout.

The virtual Congress will also present a virtual Exhibition, as well as virtual Networking Lounges and the usual programme of industry sponsored Satellite Symposia. We are most grateful to our loyal sponsors for their support in this new endeavour and are glad to be able to still have the opportunity to engage directly with them during the annual meeting.

We very much hope that you will join us at this year’s first virtual EURETINA Congress and encourage you to avail of the reduced registration rates until September 25th.

With very best wishes,

Prof. Frank G. Holz, FEBO, FARVO
President, EURETINA

Registration Information

Do you have a VAT number? If so, please contact registration@euretina.org for information on how to register. Please also contact us if you are a registered business located outside of the EU.

If you are an EURETINA Member or have submitted an abstract, you may already have an account.

If you do not know the login details for this account, please click on the ‘Forgot password’ link on the registration page and they will be sent to you. Alternatively, contact the Registration Department.

Prices are in Euro & listed without VAT
VAT is charged at 20%
EARLY FEE
5 Aug – 25 Sept
LATE FEE
26 Sept – 4 Oct
EURETINA Member 50 65
Non – Member 95 110
Ophthalmic Nurse / Technician* 50 65

*Documentation such as a work ID or verification letter from your hospital is required and must be uploaded during the registration process for approval.

Additional Info Categories Groups Cancellations

Keynote Lectures – EURETINA 2020 Virtual

Richard Spaide USA speakerfeature EURETINA Lecture Richard Spaide USA
Marta S. FigueroaKreissig LectureMarta S. FigueroaSPAIN
Stanislao RizzoGisbert Richard Lecture Stanislao RizzoITALY

src

Safety Review Committee (SRC) Report

Post-marketing reports have highlighted the occurrence of intraocular inflammation (IOI) in association with retinal vasculitis and retinal vascular occlusion with brolucizumab, which differs from the common experience with other approved anti-VEGF agents.

A Safety Review Committee (SRC) consisting of clinical trial, imaging, and uveitis experts as well as Data Monitoring Committee members was established by Novartis to independently review these post-marketing cases.

View Report

Sign up to EURETINA


© EURETINA All rights reserved
Loading please wait